Gilman Hill Asset Management’s AstraZeneca AZN Stock Holding History

Gilman Hill Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,579	Closed	-$290K	–	228
2025 Q4	$290K	Hold	1,579	–	–	0.05%	185
2025 Q3	$242K	Hold	1,579	–	–	0.04%	202
2025 Q2	$221K	Buy	+1,579	New	+$221K	0.04%	213
2024 Q4	–	Sell	-1,852	Closed	-$289K	–	221
2024 Q3	$289K	Buy	1,852 +563	+44%	+$90.9K	0.05%	179
2024 Q2	$201K	Sell	1,289 -563	-30%	-$84.7K	0.04%	202
2024 Q1	$251K	Buy	+1,852	New	+$245K	0.05%	188
2023 Q3	–	Sell	-1,852	Closed	-$265K	–	206
2023 Q2	$265K	Hold	1,852	–	–	0.05%	176
2023 Q1	$257K	Hold	1,852	–	–	0.05%	177
2022 Q4	$251K	Sell	1,852 -1,015	-35%	-$127K	0.05%	186
2022 Q3	$314K	Sell	2,867 -125	-4%	-$15.9K	0.07%	166
2022 Q2	$395K	Buy	2,992 +750	+33%	+$98.4K	0.08%	150
2022 Q1	$297K	Hold	2,242	–	–	0.07%	170
2021 Q4	$261K	Hold	2,242	–	–	0.06%	189
2021 Q3	$269K	Buy	+2,242	New	+$261K	0.07%	177
2019 Q1	–	Sell	-2,925	Closed	-$222K	–	189
2018 Q4	$222K	Hold	2,925	–	–	0.09%	153
2018 Q3	$231K	Hold	2,925	–	–	0.09%	152
2018 Q2	$205K	Buy	+2,925	New	+$210K	0.08%	160

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Gilman Hill Asset Management's AZN Position: Q1 2026 in Review

Gilman Hill Asset Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,579 shares — an estimated $290K sold.

Gilman Hill Asset Management first reported a position in AZN in Q2 2018 and held it in 17 quarters. The position peaked at $395K in Q2 2022. 1,385 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Gilman Hill Asset Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Gilman Hill Asset Management sold 1,579 AstraZeneca shares in Q1 2026, an estimated $290K.
Gilman Hill Asset Management first reported a position in AstraZeneca in Q2 2018 and held it in 17 quarters.
Gilman Hill Asset Management's AstraZeneca position peaked at $395K in Q2 2022.
1,385 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Gilman Hill Asset Management's 13F filing for Q1 2026, filed 8 Apr 2026.